SEQUENT SCIENTIFIC LTD.

Viyash Scientific Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be closed from July 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The exact date of the board meeting to approve these results will be communicated separately.

Viyash Scientific Limited, through its subsidiary Alivira Animal Health Limited, has agreed to acquire 100% of BioForLife Italia S.r.l. (BFL) for approximately ₹188 crore. This acquisition marks a strategic entry into Italy's companion animal health market, one of Europe's largest. BFL specializes in pet care products, including nutritional complements, pharmaceuticals, and diagnostic tests, with strong reach to veterinary clinics. The deal is expected to close in Q2 FY27 and is anticipated to accelerate Viyash's global pet care growth by expanding Alivira's European presence and providing a platform for new product launches.

Viyash Scientific Ltd, through its step-down subsidiary Alivira Animal Health Limited, Ireland, has entered into a binding agreement to acquire 100% shareholding of BioForLife Italia s.r.l. for an aggregate consideration of EUR 16.975 million. The acquisition includes EUR 15.0 million payable at closing and EUR 1.975 million as deferred consideration. BioForLife Italia, based in Milan, Italy, is engaged in the marketing and distribution of animal health and veterinary products, with reported annual sales of approximately EUR 9.0 million in CY 2025. This strategic move aims to strengthen Viyash Scientific's presence in the Italian companion animal segment by leveraging BioForLife's established platform and customer reach. The transaction is subject to customary conditions precedent and regulatory approvals, including notification under Italian Golden Power Laws. Initial closing is expected within three months.

Viyash Scientific Ltd (formerly Sequent Scientific Limited) announced its financial results for the period ended March 31, 2026. Q4 FY26 revenues reached ₹9,200 Million, up by 19.1%, with EBITDA at ₹2,001 Million, up 63.8%. FY26 revenues were ₹34,203 Million, up by 13.8%, and EBITDA at ₹7,025 Million, up 59.6%. FY26 PAT increased by 1324% to ₹2,246 Million. The company will conduct an earnings call on May 20, 2026.

Viyash Scientific Ltd's board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. They also adopted new Articles of Association, subject to shareholder approval, and granted 1,30,98,000 stock options to eligible employees under the "Viyash Scientific Limited Employee Stock Option Scheme 2026." No dividend was recommended for FY 2025-26. The meeting concluded at 4:56 p.m.

Viyash Scientific Ltd. has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board approved the results at its meeting on May 19, 2026. Additionally, a new set of Articles of Association was adopted, subject to shareholder approval. The board also approved the grant of 1,30,98,000 stock options to eligible employees under the "Viyash Scientific Limited Employee Stock Option Scheme 2026." No dividend was recommended for FY 2025-26. The company is not considered a Large Corporate for FY 2025-26.

Viyash Scientific Ltd. announced the demise of Mr. Phillip Trott, AVP – Legal and Compliance and a member of the senior management, on May 15, 2026. This disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Viyash Scientific Ltd has scheduled a Board of Directors meeting on May 19, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend, if any, on the company's equity shares for the same period. The trading window remains closed until 48 hours after the announcement of the financial results, i.e., up to May 21, 2026.

Viyash Scientific Ltd has appointed Mr. Amit Jain and Mr. Abhiroop Jayanthi, both representing Carlyle group, as Additional Directors (Non-Executive, Non-Independent) effective April 22, 2026. These appointments, based on the recommendation of the Nomination and Remuneration Committee, are subject to shareholder approval. The company also approved a revised ESOP pool of 1,30,98,000 stock options under ESOP 2026.

Viyash Scientific Ltd has officially changed its website domain name from www.sequent.in to www.viyash.com, effective immediately. This change also impacts the email addresses of its Directors and Key Managerial Personnel responsible for disclosures, which have been updated from @sequent.in to @viyash.com. The company has made this announcement in compliance with SEBI Listing Regulations, 2015, ensuring all stakeholders are aware of the updated contact information and online presence.